证券日报网讯 可孚医疗8月26日发布公告，在公司回答调研者提问时表示，深耕家用医疗器械近二十 载，公司已逐步构建起覆盖健康监测、康复辅具、呼吸支持、医疗护理及中医理疗五大领域的完善产品 矩阵，同时构建了以数据为驱动、全渠道协同的运营体系，数十款核心品类在主流电商平台长期稳居销 量前列。公司积极通过内部调整、精细化运营，各平台核心品类保持了良好增长。近年来，兴趣电商平 台凭借创新内容迅速崛起，拥有庞大的用户群体。公司也加大对兴趣电商平台的投入，通过短视频、直 播等形式，直观展示医疗器械产品功能和使用方法，具有良好的品牌传播和产品销售功能，能够深入挖 掘用户的潜在需求，提升医疗器械产品的渗透率。 （编辑 王雪儿） ...

Core Viewpoint - The company, Kewei Medical, is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and brand influence [2][3]. Group 1: Company Overview - Kewei Medical specializes in the research, production, sales, and service of medical devices, covering health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine [2]. - The company was listed on the A-share market in October 2021, achieving a net profit of approximately 429 million yuan that year, but experienced a decline in the following two years, with a recovery to 312 million yuan in 2024 [2][6]. Group 2: Internationalization Strategy - The management has indicated that the H-share issuance aligns with national policies supporting companies to "go global," and the Hong Kong market offers a high degree of internationalization and quality financing opportunities [3]. - The company aims to enhance its overseas business capabilities and optimize cross-border mergers and acquisitions through the establishment of the H-share platform [3]. Group 3: Recent Acquisitions - In the first half of the year, Kewei Medical completed acquisitions of Shanghai Huazhou and Ximaner, which are expected to strengthen its overseas business resources [2][4]. - Shanghai Huazhou, established in 2002, is a well-known domestic manufacturer of pressure-sensitive adhesive products, with over 60% of its revenue coming from overseas [4]. - Ximaner, founded in 1988, operates retail and wholesale medical device centers in Hong Kong, enhancing Kewei Medical's market presence [5]. Group 4: Financial Performance - In 2024, Kewei Medical reported revenues of 2.983 billion yuan, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.6% [6]. - The company’s domestic revenue accounted for approximately 98.02% of total revenue, while overseas revenue was only about 59.15 million yuan, indicating that international operations are still in the development phase [6]. - The company has experienced significant fluctuations in performance since its IPO, with net profit dropping to approximately 254 million yuan in 2023 after a peak in 2021 [6]. Group 5: Recent Challenges - In the first quarter of the current year, Kewei Medical's revenue decreased by 8.59% to approximately 738 million yuan, and net profit fell by 9.68% to about 91.43 million yuan [7]. - The company’s sales expenses increased by 31.4% to approximately 973 million yuan, primarily due to the expansion of its retail network and increased marketing investments [6][7].

Core Viewpoint - Company Kefu Medical is planning to issue H-shares and list on the Hong Kong Stock Exchange, aiming to raise funds primarily for product R&D and global sales network expansion [1] Group 1: Company Overview - Kefu Medical's latest stock price is 38.05 yuan, reflecting a 1.47% increase from the previous trading day [1] - The company specializes in the R&D, production, and sales of medical devices, covering areas such as rehabilitation aids, medical care, and traditional Chinese medicine therapy [1] Group 2: Financial Performance - In 2024, Kefu Medical is projected to achieve revenue of 2.983 billion yuan, with overseas business revenue of 59.15 million yuan, accounting for 1.98% of total revenue [1] - In Q1 2025, the company's operating revenue was 738 million yuan, representing a year-on-year decline of 8.59%, while net profit was 91.425 million yuan, down 9.68% year-on-year [1] - The company stated that its operational performance remained stable in Q2 [1] Group 3: Strategic Moves - To expand its overseas market presence, Kefu Medical has completed acquisitions of Shanghai Huazhou and Ximaner, with Shanghai Huazhou's overseas revenue accounting for over 60% [1]

Core Viewpoint - The company, KeFu Medical, is planning to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its global strategy and enhance its overseas business capabilities and brand recognition [1][4]. Group 1: Company Overview - KeFu Medical is a comprehensive personal health management enterprise engaged in the research, production, sales, and service of medical devices, covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy [3]. - The company's main brand "KeFu" includes sub-brands such as "JianEr Hearing," "JiRui Medical," "BeiBeiJia," "YanBenShu," and "YangLiDe" [3]. Group 2: Financial Performance - In the first quarter of this year, KeFu Medical reported a revenue of approximately 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of about 91.43 million yuan, down 9.68% year-on-year [6]. - The company's revenue from overseas markets was approximately 5.91 million yuan in 2024, accounting for only 1.98% of total revenue, indicating that its overseas business is still in the cultivation stage [4]. Group 3: Strategic Intentions - The decision to list on the Hong Kong Stock Exchange aligns with national policies supporting companies going global and aims to enhance the company's international development [4]. - The company has completed acquisitions of Shanghai Huazhou and Ximan Na, which are expected to strengthen its overseas business resources [5]. - Future overseas acquisitions will focus on companies that can supplement product lines or enhance technological capabilities, as well as those with established distribution networks or brand influence [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's core products are experiencing steady growth, while short-term profits are under pressure due to the performance of the hearing aid segment [5][7] - The company is expected to focus on core products and self-manufactured items, with a rich product pipeline that is likely to enhance profitability in the future [7] Financial Performance Summary - For 2023, the company reported revenue of 2,854 million RMB, with a year-on-year decline of 4.14%. The net profit attributable to the parent company was 254 million RMB, down 15.71% year-on-year [6] - Revenue is projected to grow to 3,495 million RMB in 2025, representing a year-on-year increase of 17.15%. The net profit is expected to reach 376 million RMB, with a growth rate of 20.45% [6][8] - The gross margin for 2024 is reported at 51.9%, an increase of 8.6 percentage points year-on-year, with significant improvements in the rehabilitation aids segment [7] Business Segment Performance - The rehabilitation aids segment achieved revenue of 1.1 billion RMB, up 42.8% year-on-year. The traditional Chinese medicine therapy and other segments generated 180 million RMB, up 20.5% year-on-year [7] - The hearing aid segment reported revenue of 270 million RMB, a year-on-year increase of 37.9%, but also faced a net loss of 43.25 million RMB due to a challenging consumer environment and new store performance [7] Profitability and Valuation - The company is expected to see net profits of 3.8 billion RMB, 4.5 billion RMB, and 5.4 billion RMB from 2025 to 2027, with growth rates of 20.4%, 20.2%, and 20.6% respectively [7] - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 19X, 16X, and 13X respectively [7]